ABOUND.2L+: A randomized phase 2 study of nanoparticle albumin‐bound paclitaxel with or without CC‐486 as second‐line treatment for advanced nonsquamous non‐small cell lung cancer (NSCLC)
<p><strong>Background</strong> This randomized phase 2 trial compared the efficacy and safety of second‐line nanoparticle albumin‐bound paclitaxel (nab‐paclitaxel) with or without the addition of CC‐486 (an oral formulation of 5‐azacytidine) in patients with advanced‐stage, nonsqua...
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Wiley
2018
|
| _version_ | 1797099285509046272 |
|---|---|
| author | Morgensztern, D Cobo, M Ponce Aix, S Postmus, PE Lewanski, CR Bennouna, J Fischer, JR Juan-Vidal, O Stewart, DJ Fasola, G Ardizzoni, A Bhore, R Wolfsteiner, M Talbot, DC Jin Ong, T Govindan, R On Behalf Of The Abound L Investigators |
| author_facet | Morgensztern, D Cobo, M Ponce Aix, S Postmus, PE Lewanski, CR Bennouna, J Fischer, JR Juan-Vidal, O Stewart, DJ Fasola, G Ardizzoni, A Bhore, R Wolfsteiner, M Talbot, DC Jin Ong, T Govindan, R On Behalf Of The Abound L Investigators |
| author_sort | Morgensztern, D |
| collection | OXFORD |
| description | <p><strong>Background</strong>
This randomized phase 2 trial compared the efficacy and safety of second‐line nanoparticle albumin‐bound paclitaxel (nab‐paclitaxel) with or without the addition of CC‐486 (an oral formulation of 5‐azacytidine) in patients with advanced‐stage, nonsquamous non‐small cell lung cancer.</p>
<p><strong>Methods</strong>
Patients were randomized to receive either nab‐paclitaxel 100 mg/m2 on days 8 and 15 plus CC‐486 200 mg daily on days 1 to 14 or single‐agent nab‐paclitaxel 100 mg/m2 on days 1 and 8, with both regimens administered every 21 days until tumor progression or unacceptable toxicity. The primary endpoint was progression‐free survival. Secondary endpoints included the overall response rate, the disease control rate, and overall survival.</p>
<p><strong>Results</strong>
Between January 2015 and August 2016, 161 patients were randomized (81 to the combination arm and 80 to the single‐agent nab‐paclitaxel arm). There was no benefit from the addition of CC‐486 to nab‐paclitaxel. The median progression‐free survival was 3.2 months for the combination and 4.2 months for single‐agent nab‐paclitaxel (hazard ratio, 1.3; 95% confidence interval, 0.9‐1.9). The median overall survival was 8.1 months in the combination arm and 17 months in the single‐agent nab‐paclitaxel arms (hazard ratio, 1.7; 95% confidence interval, 1.08‐2.57). Grade 3 or greater treatment‐related, emergent adverse events were reported by 40.5% of patients in the combination arm and by 31.6% of those in the single‐agent nab‐paclitaxel arm.</p>
<p><strong>Conclusions</strong>
Single‐agent nab‐paclitaxel was associated with promising outcomes and a tolerable safety profile as second‐line treatment for patients with advanced‐stage, nonsquamous non‐small cell lung cancer. There was no benefit from the addition of CC‐486 to nab‐paclitaxel.</p> |
| first_indexed | 2024-03-07T05:21:36Z |
| format | Journal article |
| id | oxford-uuid:df1d63a8-32ea-4af7-9d79-8d44b3b37cd7 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T05:21:36Z |
| publishDate | 2018 |
| publisher | Wiley |
| record_format | dspace |
| spelling | oxford-uuid:df1d63a8-32ea-4af7-9d79-8d44b3b37cd72022-03-27T09:37:07ZABOUND.2L+: A randomized phase 2 study of nanoparticle albumin‐bound paclitaxel with or without CC‐486 as second‐line treatment for advanced nonsquamous non‐small cell lung cancer (NSCLC)Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:df1d63a8-32ea-4af7-9d79-8d44b3b37cd7EnglishSymplectic ElementsWiley2018Morgensztern, DCobo, MPonce Aix, SPostmus, PELewanski, CRBennouna, JFischer, JRJuan-Vidal, OStewart, DJFasola, GArdizzoni, ABhore, RWolfsteiner, MTalbot, DCJin Ong, TGovindan, ROn Behalf Of The Abound L Investigators<p><strong>Background</strong> This randomized phase 2 trial compared the efficacy and safety of second‐line nanoparticle albumin‐bound paclitaxel (nab‐paclitaxel) with or without the addition of CC‐486 (an oral formulation of 5‐azacytidine) in patients with advanced‐stage, nonsquamous non‐small cell lung cancer.</p> <p><strong>Methods</strong> Patients were randomized to receive either nab‐paclitaxel 100 mg/m2 on days 8 and 15 plus CC‐486 200 mg daily on days 1 to 14 or single‐agent nab‐paclitaxel 100 mg/m2 on days 1 and 8, with both regimens administered every 21 days until tumor progression or unacceptable toxicity. The primary endpoint was progression‐free survival. Secondary endpoints included the overall response rate, the disease control rate, and overall survival.</p> <p><strong>Results</strong> Between January 2015 and August 2016, 161 patients were randomized (81 to the combination arm and 80 to the single‐agent nab‐paclitaxel arm). There was no benefit from the addition of CC‐486 to nab‐paclitaxel. The median progression‐free survival was 3.2 months for the combination and 4.2 months for single‐agent nab‐paclitaxel (hazard ratio, 1.3; 95% confidence interval, 0.9‐1.9). The median overall survival was 8.1 months in the combination arm and 17 months in the single‐agent nab‐paclitaxel arms (hazard ratio, 1.7; 95% confidence interval, 1.08‐2.57). Grade 3 or greater treatment‐related, emergent adverse events were reported by 40.5% of patients in the combination arm and by 31.6% of those in the single‐agent nab‐paclitaxel arm.</p> <p><strong>Conclusions</strong> Single‐agent nab‐paclitaxel was associated with promising outcomes and a tolerable safety profile as second‐line treatment for patients with advanced‐stage, nonsquamous non‐small cell lung cancer. There was no benefit from the addition of CC‐486 to nab‐paclitaxel.</p> |
| spellingShingle | Morgensztern, D Cobo, M Ponce Aix, S Postmus, PE Lewanski, CR Bennouna, J Fischer, JR Juan-Vidal, O Stewart, DJ Fasola, G Ardizzoni, A Bhore, R Wolfsteiner, M Talbot, DC Jin Ong, T Govindan, R On Behalf Of The Abound L Investigators ABOUND.2L+: A randomized phase 2 study of nanoparticle albumin‐bound paclitaxel with or without CC‐486 as second‐line treatment for advanced nonsquamous non‐small cell lung cancer (NSCLC) |
| title | ABOUND.2L+: A randomized phase 2 study of nanoparticle albumin‐bound paclitaxel with or without CC‐486 as second‐line treatment for advanced nonsquamous non‐small cell lung cancer (NSCLC) |
| title_full | ABOUND.2L+: A randomized phase 2 study of nanoparticle albumin‐bound paclitaxel with or without CC‐486 as second‐line treatment for advanced nonsquamous non‐small cell lung cancer (NSCLC) |
| title_fullStr | ABOUND.2L+: A randomized phase 2 study of nanoparticle albumin‐bound paclitaxel with or without CC‐486 as second‐line treatment for advanced nonsquamous non‐small cell lung cancer (NSCLC) |
| title_full_unstemmed | ABOUND.2L+: A randomized phase 2 study of nanoparticle albumin‐bound paclitaxel with or without CC‐486 as second‐line treatment for advanced nonsquamous non‐small cell lung cancer (NSCLC) |
| title_short | ABOUND.2L+: A randomized phase 2 study of nanoparticle albumin‐bound paclitaxel with or without CC‐486 as second‐line treatment for advanced nonsquamous non‐small cell lung cancer (NSCLC) |
| title_sort | abound 2l a randomized phase 2 study of nanoparticle albumin bound paclitaxel with or without cc 486 as second line treatment for advanced nonsquamous non small cell lung cancer nsclc |
| work_keys_str_mv | AT morgenszternd abound2larandomizedphase2studyofnanoparticlealbuminboundpaclitaxelwithorwithoutcc486assecondlinetreatmentforadvancednonsquamousnonsmallcelllungcancernsclc AT cobom abound2larandomizedphase2studyofnanoparticlealbuminboundpaclitaxelwithorwithoutcc486assecondlinetreatmentforadvancednonsquamousnonsmallcelllungcancernsclc AT ponceaixs abound2larandomizedphase2studyofnanoparticlealbuminboundpaclitaxelwithorwithoutcc486assecondlinetreatmentforadvancednonsquamousnonsmallcelllungcancernsclc AT postmuspe abound2larandomizedphase2studyofnanoparticlealbuminboundpaclitaxelwithorwithoutcc486assecondlinetreatmentforadvancednonsquamousnonsmallcelllungcancernsclc AT lewanskicr abound2larandomizedphase2studyofnanoparticlealbuminboundpaclitaxelwithorwithoutcc486assecondlinetreatmentforadvancednonsquamousnonsmallcelllungcancernsclc AT bennounaj abound2larandomizedphase2studyofnanoparticlealbuminboundpaclitaxelwithorwithoutcc486assecondlinetreatmentforadvancednonsquamousnonsmallcelllungcancernsclc AT fischerjr abound2larandomizedphase2studyofnanoparticlealbuminboundpaclitaxelwithorwithoutcc486assecondlinetreatmentforadvancednonsquamousnonsmallcelllungcancernsclc AT juanvidalo abound2larandomizedphase2studyofnanoparticlealbuminboundpaclitaxelwithorwithoutcc486assecondlinetreatmentforadvancednonsquamousnonsmallcelllungcancernsclc AT stewartdj abound2larandomizedphase2studyofnanoparticlealbuminboundpaclitaxelwithorwithoutcc486assecondlinetreatmentforadvancednonsquamousnonsmallcelllungcancernsclc AT fasolag abound2larandomizedphase2studyofnanoparticlealbuminboundpaclitaxelwithorwithoutcc486assecondlinetreatmentforadvancednonsquamousnonsmallcelllungcancernsclc AT ardizzonia abound2larandomizedphase2studyofnanoparticlealbuminboundpaclitaxelwithorwithoutcc486assecondlinetreatmentforadvancednonsquamousnonsmallcelllungcancernsclc AT bhorer abound2larandomizedphase2studyofnanoparticlealbuminboundpaclitaxelwithorwithoutcc486assecondlinetreatmentforadvancednonsquamousnonsmallcelllungcancernsclc AT wolfsteinerm abound2larandomizedphase2studyofnanoparticlealbuminboundpaclitaxelwithorwithoutcc486assecondlinetreatmentforadvancednonsquamousnonsmallcelllungcancernsclc AT talbotdc abound2larandomizedphase2studyofnanoparticlealbuminboundpaclitaxelwithorwithoutcc486assecondlinetreatmentforadvancednonsquamousnonsmallcelllungcancernsclc AT jinongt abound2larandomizedphase2studyofnanoparticlealbuminboundpaclitaxelwithorwithoutcc486assecondlinetreatmentforadvancednonsquamousnonsmallcelllungcancernsclc AT govindanr abound2larandomizedphase2studyofnanoparticlealbuminboundpaclitaxelwithorwithoutcc486assecondlinetreatmentforadvancednonsquamousnonsmallcelllungcancernsclc AT onbehalfoftheaboundlinvestigators abound2larandomizedphase2studyofnanoparticlealbuminboundpaclitaxelwithorwithoutcc486assecondlinetreatmentforadvancednonsquamousnonsmallcelllungcancernsclc |